Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens STIC was found (1.8%, 95%-CI 0.00-5.16), however she carried an unclassified variant in BRCA2. Total follow-up after RRSO was 1691 woman-years, in which one BRCA1-carrier developed peritoneal cancer (0.3%, 95%-CI 0.00-0.82). Conclusions: A low prevalence of occult invasive cancer (1.1%) was found in young asymptomatic, screen-negative women at increased ovarian cancer risk undergoing RRSO. This study adds to the advice to perform RRSO in BRCA1-carriers before the age of 40. Our findings support the hypothesis of the fallopian tube as the primary site of origin of pelvic highgrade serous cancer. Ó 2012 Elsevier Ltd. All rights reserved.
Introduction
Epithelial ovarian cancer aggregates in families. A family history of ovarian cancer confers an increased risk of this disease: the lifetime risk for women with one first-degree relative affected by ovarian cancer is 3.5-7% and increases to 15% when two first-degree relatives are affected. 1 In approximately 10% of all ovarian cancer cases, a deleterious BRCA1/2 germline mutation can be detected. 2, 3 The lifetime risk of developing ovarian cancer in women with a proven BRCA1-mutation ranges from 18% to 54% and is 2.4-23% in BRCA2mutation carriers by the age of 70 years. 4, 5 Since the proven ineffectiveness of gynaecologic screening in detecting early-stage ovarian/tubal cancer, 6, 7 BRCA-carriers are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO). If performed at a young age, RRSO is associated with a statistically significant reduction of the risk of BRCA-associated ovarian/ tubal cancer (hazard ratio (HR) 0.21; 95%-confidence interval (CI) 0.12-0.39). 8 After RRSO, a residual risk may exist for 'primary' peritoneal cancer; although according to new insights peritoneal cancer is possibly metastatic from tubal intraepithelial carcinoma. 9, 10 Occult cancers have been reported in prophylactically removed ovaries and fallopian tubes in BRCA-carriers. Reported rates vary considerably from 2% to 12% 11, 12 and seem to be influenced by patients' age at RRSO, symptoms, gynaecologic screening prior to RRSO, the completeness of prophylactic surgery and the extent of histopathological examination. Non-invasive serous tubal intraepithelial carcinomas (STICs) have been identified in 3-12% of the prophylactically removed tubes of BRCA-carriers, especially in the fimbrial part. 11, 13 No intraepithelial carcinomas have ever been found in ovaries so far, suggesting that ovarian cancer does not have its origin in the ovary itself. 14 The fallopian tube is currently being suggested as the primary site of origin of pelvic high-grade serous cancer 15 , which has recently been established in a mouse model. 16 Aim of this study was to obtain an unbiased estimate of the prevalence, localisation and type of occult (non)invasive cancer in prophylactically removed ovaries and tubes in a consecutive series of BRCA-carriers and high-risk women from BRCA-negative families attending a tertiary multidisciplinary cancer clinic.
Patients and methods
The Family Cancer Clinic (FCC) at the University Medical Center Groningen (UMCG) is a tertiary level clinic for managing women at hereditary or familial high-risk for ovarian (and breast) cancer (H(B)OC). From 1996, clinical and genetic data of all high-risk families have been prospectively registered at the FCC in a combined setting by a clinical geneticist, a gynaecologic oncologist and a surgical oncologist. 17 Genetic testing for BRCA-mutations is available to women from H(B)OC families (see criteria in Fig. 1 ). 18 Women with a confirmed BRCA-mutation are being counselled to consider RRSO from the age of 35 (BRCA1) or 40 (BRCA2), or as soon as childbearing after this age is completed. 18 Women from a H(B)OC family who tested negative for BRCA-mutations (further denoted 'BRCAnegative high-risk women') are also offered RRSO if the estimated lifetime risk of developing ovarian cancer is >10%. After RRSO, women still visit the FCC for breast cancer screening by a surgical oncologist. 19 A consecutive series of RRSO specimens of BRCA1carriers, BRCA2-carriers and BRCA-negative high-risk women were prospectively collected in the UMCG between 1st January 2000 and 1st March 2012. Included were asymptomatic women who had a negative gynaecologic screening (pelvic examination, transvaginal ultrasound and serum CA125 measurement) within 1 year prior to RRSO. 7 Excluded were women with ovarian/tubal cancer prior to RRSO and women who underwent salpingo-oophorectomy as part of breast cancer therapy. Main outcome measures were the prevalence and localisation of occult cancer and STIC (primary outcomes), and of atypical hyperplasia (secondary outcome). 20 An anonymous, password-protected database was used to enter the data. Protection of the patients' identity was guaranteed by assigning study-specific, unique patient numbers and codes were only known to two dedicated data managers. According to Dutch law, no further Institutional Review Board approval was needed for this study.
A strict surgico-pathological protocol was applied consisting of complete resection of both tubes and ovaries that were transversely sectioned at 2-3 mm intervals and processed in their entirety. 21 Since Madeiros et al. in 2006 published a protocol for sectioning and extensively examining the fimbrial end (SEE-FIM), this protocol was implemented in our study. 22 From the ovaries and fallopian tubes a small part was snap frozen for the tissue bank, as according to the protocol, a haematoxylin and eosin (H&E) section was made to check for histological abnormalities and additional immunohistochemical staining of p53 and MIB-1 (Ki67) was performed. Histopathological examination was conducted by two expert gynaecologic pathologists (H.H. and J.B.) who were aware of the woman's mutation status. The H&E sections showing morphologically atypical epithelium, STIC or occult cancer and a sample of normal sections, were independently revised by the other expert gynaecologic pathologist without knowledge of the previous pathologic report.
Occult cancer was defined as a clinically unapparent invasive malignancy of the epithelium of the ovary or fallopian tube diagnosed at histopathological examination, according to the guidelines of the International Federation of Gynecology and Obstetrics (FIGO). In this paper, occult cancer refers to an invasive malignancy and not to an in situ component. STIC was defined as an intraepithelial carcinoma that was in continuity with normal mucosal epithelium, with epithelial stratification, nuclear enlargement, prominent nucleoli, variable loss of epithelial polarity and mitotic activity ( Fig. 2D-F ). 23 Cases with histological abnormalities not amounting to STIC, but showing some cellular crowding, stratification, loss of nuclear polarity and moderate to severe nuclear atypia, were defined as atypical hyperplasia ( Fig. 2A-C) . 20 Positive staining for p53 was not required for diagnosing atypical hyperplasia. All BRCA1-mutation carriers presented in this paper had a proven pathogenic mutation (splice site mutations, nonsense mutations, frameshifts or exon deletions). Patients carrying an unclassified variant (UV) were incorporated in the group 'negative tested women'. The start of follow-up after RRSO was defined as the date of RRSO and the end of follow-up as the date of the last outpatient visit.
Statistical analysis was performed using SPSS 18.0 for Windows (SPSS, Chicago, IL). Descriptive values of variables were expressed as frequencies and percentages for discrete data and as median and range for continuous data. Differences between the groups were investigated with the v2 test or Fisher's exact test for discrete variables and with the Mann Whitney U test or Kruskall-Wallis test for continuous data. For each woman, duration of follow-up was calculated. Confidence intervals for a single proportion were calculated and P-values <0.05 were considered to be statistically significant.
Results
From January 2000 until March 2012, 641 women from high-risk families visited our FCC after referral by the clinical genetics department. In total, 360 women underwent RRSO, among whom were 188 BRCA1carriers (52.2%) from 221 BRCA1-families, 115 BRCA2-carriers (31.9%) from 146 BRCA2-families and 57 BRCA-negative high-risk women (15.8%) from 45 BRCA-negative high-risk families (reference date: 1st March 2012) ( Table 1 ). Of the BRCA-negative women, five had a UV in one of the BRCA-genes. Median age at RRSO was 44.0 (range 30-72); BRCA1-carriers were significantly younger (42.0) than BRCA2-carriers (45.0) and BRCA-negative women (47.0; p < 0.001). Thirtyeight percent of the women had previously been diagnosed with breast cancer. Histomorphological findings in RRSO specimens are presented in Table 2 . Occult cancer was detected in four women: two fallopian tube and two ovarian cancers. All were BRCA1-carriers and above the age of 40 (median age 55.0) ( Table 3 ). The overall occult cancer rate was 1.1% (95%-CI 0.03-2.19), the rate in BRCA-carriers was 1.3% (95%-CI 0.03-2.61) and in BRCA1-carriers 2.2% (95%-CI 0.11-4.32). All four patients underwent a surgical staging procedure and all cancers appeared to be early stage (FIGO I/II). Patients were treated with adjuvant chemotherapy (six courses of paclitaxel and carboplatin). No slides or tissue blocks of distal tubes were available from both occult ovarian cancers, most probably because the tissue was used for other research properties; therefore a tubal origin could not be excluded nor proven with certainty.
Four cases of STIC (as shown in Fig. 2D -F) were detected, all located in the fallopian tube (1.1%, 95%-CI 0.03-2.19): one in a BRCA1-carrier (aged 60 years), two in BRCA2-carriers (aged 50 and 57 years) and one in a BRCA-negative woman (aged 56 years; median age 56.5) ( Table 3 ). The STIC rate in BRCA-carriers was 1.0% (95%-CI 0.00-2.10) and was 1.8% (95%-CI 0.00-5.16) in BRCA-negative women.
Atypical hyperplasia (as shown in Fig. 2A -C) was present in 23 women (6.4%, 95%-CI 3.86-8.96): 13 BRCA1, nine BRCA2 and one BRCA-negative woman (median age 41.0) ( Table 4 ). Rates were 7.2% (95%-CI 4.34-10.18) for BRCA-carriers and 1.8% (95%-CI 0.00-5.16) for BRCA-negative women. Seventeen out of 23 lesions were localised in the fimbrial end of the tube (73.9%). The other six atypical lesions also concerned tubal epithelium either located at the ovarian surface or lining epithelial ovarian inclusion cysts. The case of STIC and the case of atypia were found in two BRCA-negative high-risk women who however carried a suspected pathogenic (category III) and a possibly pathogenetic (category II) UV in BRCA, respectively. The case of STIC concerned a 56-year-old woman with a maternal breast/ovarian cancer family, however with a (probably) paternal UV in BRCA2 (ALA2306Pro) who was diagnosed with breast cancer at the age of 28. The case of atypical hyperplasia concerned a 37-year-old woman with a UV in BRCA1 (332-15A>G), from a maternal breast/ovarian cancer family. Incidental benign alterations were seen in approximately 40% of the women, without significant differences between BRCA-carriers and negative tested women.
The total follow-up after RRSO concerned 1691 woman years, with a median follow-up of 5.0 years (range 0-12) per woman. Specifically, the four patients with occult carcinoma had a median follow-up of 7.5 years (range 6-10), the four patients with STIC had a median follow-up of 1.0 years (range 0-6) and the 23 women with atypical hyperplasia had a median follow-up of 5.0 years (range 0-11). None of the women with STIC or atypical hyperplasia developed peritoneal cancer. One patient, carrying a BRCA1-mutation, developed peritoneal cancer 4.2 years after a RRSO (0.3%, 95%-CI 0.00-0.82). Careful histological re-examination of the ovaries and tubes (including immunohistochemical staining of p53 and MIB-1) was performed, which assured the complete removal of both ovaries and tubes, and revealed atypical hyperplasia in the left distal fallopian tube.
Discussion
To date, this is the largest consecutive series of prospectively collected RRSO specimens in BRCA-carriers and BRCA-negative high-risk women attending a tertiary multidisciplinary cancer clinic. Our study showed a low prevalence of occult cancer (1.1%) and STIC (1.1%), exclusively in BRCA-carriers or women with a UV. Two of the four cancers could be proven to originate from the fallopian tube, and all STICs and atypical hyperplastic lesions were derived from tubal epithelium. Strengths of this study are the consecutive and uniform series of asymptomatic, screen-negative high-risk women, the independent histopathological revision of the morphologically deviant sections by another expert gynaecologic pathologist, the clear distinction between BRCA-positive and BRCA-negative cases, the large sample-size, the prospective nature of the study and the long duration of follow-up. A limitation was the unavailability of two specimens for histopathological revision.
We found a low prevalence of occult cancer at RRSO of 1.3% in BRCA-carriers. Reported prevalence of occult cancer in BRCA-carriers varies considerably, from 2% to 3% in large, mainly multicentre series, 9, 12, 13, 24, 25 to 7% to 12% in smaller, particularly single-centre series. 11, 26, 27 The lower cancer prevalence in our series might be explained by age at RRSO, which was 43 years in our series compared to approximately 48 years in the latter. 11, [26] [27] [28] Furthermore, the majority of these studies did not select women on absence of symptoms for the presence of ovarian cancer, nor performed gynaecological screening prior to RRSO routinely and advanced stage cancers were not uncommon. 11, 26, 27 We believe that the selection of young, asymptomatic, screen-negative women for In 1 BRCA1 and 3 BRCA2 mutation carriers RRSO was performed before mutation status was known. * Including five women with UV mutation in one of the BRCA genes: two unlikely pathogenic (category 2 UV) and three possibly pathogenic (category 3 UV) (Bell's classification). à Atypical cells: this patient was diagnosed with endometrioid type endometrial cancer 7 months after RRSO (n = 1). # BRCA1 due to ovarian (n = 1) and breast cancer (n = 4); BRCA2 due to breast cancer (n = 1), pancreas cancer (n = 1) and a non-malignant cause (n = 1); negative tested due to breast cancer (n = 1). Para tubal cysts  37  -22  -13  -72  -Papillomatosis  -1  -3  -3  -7  Adenofibroma  2  4  -6  -3  2  13  Serous cystadenoma  -6  -1  -4  -11  Dermoid cyst  -3  -1  -2  -6  Brenner tumor  -4  -1  -1  -6  Haemangioma  -1  -1  ---2  Endometriosis  -2  1  5  1  5  2  12  Endosalpingiosis  2  -2  ---4  -Walthard cell rest  17  1  11  1  7  2  35  4  Mesonephric rests  10  7  -3  2  2  12  12  Ectopic adrenal tissue  -1  -2  ---3  Leydig-cell hyperplasia  -3  -1  ---4  Rete ovarii  -3  -----3 * Including five women with UV mutation in one of the BRCA genes: two unlikely pathogenic (category 2 UV) and three possibly pathogenic (category 3 UV) (Bell's classification).
Multiple abnormalities per woman: in 33.3% (120/360) women no histomorphological abnormalities were found; 35.8% (129/360) women had one lesion (carcinoma, STIC, atypical, reactive or benign); 20.8% (75/360) had two different lesions; 10.0% (36/360) had three or more different lesions.
RRSO, contributes to the finding of a low occult cancer frequency at RRSO.
Occult cancers in our series were exclusively found in BRCA1-carriers above age 40 (2.2%). This is consistent with literature and can be explained by the higher penetrance of ovarian cancer in BRCA1-as compared to BRCA2-carriers. 9, 13, 25, 29 Three STICs were detected in BRCA-carriers (1.0%): one in a BRCA1-carrier and two in BRCA2-carriers. STIC has been reported in 3-12% of the prophylactically removed ovaries and fallopian tubes in BRCA-carriers, mostly in the fimbrial end of the tube. 11, 13, 28, [30] [31] [32] Our finding of 1.0% STICs in BRCA-carriers is at the lower end of the reported range, which could be explained by the consecutive series of asymptomatic carriers (no case-finding), the relatively young age at RRSO and the strict definitions used. Twenty-three atypical hyperplastic lesions (7.2%) were detected in BRCA-carriers. In a recent clinicopathological study of 117 RRSO-specimens of BRCA-carriers, atypia was reported in five cases. 32 Limited data are available on the occult cancer rate in prophylactically removed ovaries and fallopian tubes in BRCA-negative high-risk women. Few clinicopathological RRSO studies included a small number of BRCAnegative women and none of them found occult cancer or STIC in these women. 6, 11, 12, 28, 33, 34 We found one STIC (1.8%) and one atypical hyperplastic lesion (1.8%) in BRCA-negative women; however both women had a UV BRCA-mutation. UV mutations in the BRCA-genes are a frequently occurring problem in genetic counselling of breast and/or ovarian cancer families. Data about the cancer history of the probands and their families are now being used to build a model for evaluating the clinical significance of UV mutations in the medical practice. 35 The tubal epithelium was the primary origin of half of the occult cancers, all cases of STIC and all atypical hyperplastic lesions. Other studies demonstrate at least $40% of the occult cancers being located in the (distal) fallopian tube. 9, 11, 25, 30, 31, 33, 36 In the two ovarian cancers in our series, of tubal origin could not be studied as no fallopian tube slides were available or tissue blocks seen anymore. Intraepithelial carcinoma (STIC) has only been described in the fimbrial end of the fallopian tube and never in the ovary. 14 The atypical hyperplastic lesions were either located in the fallopian tube (17/23) or were most likely derived from the fallopian tube (6/ 23), concerning atypical tubal epithelium located at the ovarian surface or lining epithelial inclusion cysts. These findings might further designate the distal fallopian tube as the primary site of high grade serous cancer.
The diagnosis of atypical hyperplasia with cytological features that fall short of STIC remains controversial. The clinical significance of these lesions in the development of ovarian cancer is unclear; however none of the women diagnosed with atypia in our study developed cancer. More patients with this finding need to be studied to determine whether it has any relationship to the development of STIC. The presence of STIC on the other hand, has been linked as being a pre-invasive phase of ovarian and peritoneal cancer. 10, 15, 23, 37 The likelihood of developing peritoneal cancer after RRSO has been estimated to be $1%. 24, 25, 31, 33, 38 During a total followup after RRSO of 1.691 woman years, one peritoneal cancer has been diagnosed in a BRCA1-carrier 4.2 years after RRSO. This low frequency of peritoneal cancer after RRSO makes it less likely that biologically significant lesions as occult cancer and STIC have been missed. Although the fallopian tube is suggested to be the primary origin of tumourigenesis in BRCA-carriers, the ovary may be the preferred site for tumours to progress beyond the microscopic stage. 29 A bilateral salpingectomy per se has recently been put forward as a temporary risk-reducing surgical procedure for BRCAcarriers, removing the tissue with the greatest malignant potential and avoiding the oestrogen deprivation symptoms of the bilateral oophorectomy. 39, 40 However, caution is needed with translating the tubal hypothesis into clinical practice before it is proven. Besides, even if the fallopian tubes are removed, dysplastic cells may have already spread to the ovary earlier, still resulting in a risk of 'ovarian' cancer. 29 Our study, covering a 12-year period, shows a low prevalence of occult cancer and STIC in young asymp-tomatic, screen-negative women at increased ovarian cancer risk undergoing RRSO. As occult cancers were exclusively found in BRCA1 above the age of 40, our findings add to the advice for BRCA1-carriers to undergo RRSO before the age of 40. In BRCA-negative high-risk women, STIC was only found in one woman with a BRCA UV. It is important that clinicians are made aware of these issues, as they have implications for counselling high-risk women. Our findings support the hypothesis of the fallopian tube as the primary site of origin of pelvic high-grade serous cancer. It also underscores the importance of complete removal and a strict histopathological sectioning protocol.
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